FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity

The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to EG110A, a gene therapy targeting neurogenic detrusor overactivity with urinary incontinence, facilitating more frequent FDA interactions and potentially accelerating its clinical development in the United States.

This Wire brief sits within Fusion42's coverage of Biotech.